MUC1 and neoplasm: As expected, compared to ppM1 alone treatment, both therapies of ppM1 in combination with either PD-1 antibody or MUC1 vaccine demonstrated further improved outcomes in the decreased tumor volumes (Figures S9F and S9H) and in the extended mouse life span (Figures S9G and S9I).